OTEurope

Preservatives in glaucoma medications

May 1, 2014

Article

Preservatives are an important component of topical multidose glaucoma medications. However, many glaucoma patients have symptoms of ocular surface disease (OSD), which can affect quality of life, treatment adherence and surgical outcomes. In this article, Prof. Baudouin offers straightforward steps to assess OSD and identify the patients most at risk.

What should the ophthalmologist do?

2. Is OSD easily spotted?

Related Videos

Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany

Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London

Kasperi Kankare at the iCare booth at ESCRS

Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase

2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent

Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in

Investigating the effects of canaloplasty on corneal epithelium

Related Content

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Ciliatech presents clinical trial results from SAFARI III glaucoma study

September 7th 2023

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

Global study reveals new key genetic targets linked to glaucoma risk

International Glaucoma Surgical Registry and Elios Vision announce partnership

Ciliatech presents data on first-generation implant at World Glaucoma Congress

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Ciliatech presents clinical trial results from SAFARI III glaucoma study

September 7th 2023

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

Global study reveals new key genetic targets linked to glaucoma risk

International Glaucoma Surgical Registry and Elios Vision announce partnership

Ciliatech presents data on first-generation implant at World Glaucoma Congress

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

Ciliatech presents clinical trial results from SAFARI III glaucoma study

September 7th 2023

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

Global study reveals new key genetic targets linked to glaucoma risk

International Glaucoma Surgical Registry and Elios Vision announce partnership

Ciliatech presents data on first-generation implant at World Glaucoma Congress

Related Content

A group of doctors and scientists walk through a laboratory. Image credit: ©Oostendorp/peopleimages.com – stock.adobe.com

Study: MERCURY-3 trial results support efficacy of Roclanda

September 13th 2023

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

An imaging device shows intraocular pressure. Image Credit: ©sompong_tom – stock.adobe.com

Ciliatech presents clinical trial results from SAFARI III glaucoma study

September 7th 2023

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

A doctor in a white coat shakes hands with someone off-screen. Image credit: ©bnenin – stock.adobe.com

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

According to the company, the deal expands its European footprint into Spain and Portugal.

A double-helix image representing genetic research. Image credit: ©Anusorn - stock.adobe.com

Global study reveals new key genetic targets linked to glaucoma risk

Hundreds of previously-unknown genes could be vital for early detection and treatment.

A screen shows a web of file folders, representing data on a digital server. Image credit: ©thodonal – stock.adobe.com

International Glaucoma Surgical Registry and Elios Vision announce partnership

The open-access tool is the official registry partner of the European Glaucoma Society.

A scientist sits at a computer, reviewing data on the screen. Image credit: ©Gorodenkoff – stock.adobe.com

Ciliatech presents data on first-generation implant at World Glaucoma Congress

Preliminary results indicate significant improvement for patients and ‘very good safety profile’

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.